Corcept Therapeutics (CORT) Net Equity Issued and Repurchased (2011 - 2023)

Corcept Therapeutics has reported Net Equity Issued and Repurchased for 12 years, with the latest figure at $1.8 million in Q4 2023.

• Quarterly Net Equity Issued and Repurchased rose 124.33% year-over-year to $1.8 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5.8 million (up 32.64% YoY) and the FY2023 annual result came in at $5.8 million, up 32.64% from the prior year.
• Net Equity Issued and Repurchased grew to $1.8 million in Q4 2023 per CORT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $10.0 million in Q4 2020 and troughed at $480000.0 in Q1 2020.
• A 5-year average of $2.9 million and a median of $1.8 million in 2019 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2022: Net Equity Issued and Repurchased soared 741.25% in 2021, then slumped 88.42% in 2022.
• Over 5 years, Net Equity Issued and Repurchased stood at $1.8 million in 2019, then surged by 462.27% to $10.0 million in 2020, then plunged by 69.49% to $3.0 million in 2021, then sank by 74.24% to $785000.0 in 2022, then soared by 124.33% to $1.8 million in 2023.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1.8 million, $1.1 million, and $1.5 million for Q4 2023, Q3 2023, and Q2 2023 respectively.